Nasdaq ikna.

Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway. The ...

Nasdaq ikna. Things To Know About Nasdaq ikna.

Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A …... (NASDAQ: IKNA). Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP). News provided by. Levi & Korsinsky, LLP. Oct 02, 2023, 5:45 AM ET. NEW YORK ...IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Check if IKNA Stock has a Buy or Sell Evaluation. IKNA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ikena Oncology, Inc. News.Follow. BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

Check if IKNA Stock has a Buy or Sell Evaluation. IKNA Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Ikena Oncology, Inc. News.

4.2100. +0.3500. +9.07%. BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer ...Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...KludeIn I Acquisition Corp. Class A Common Stock (INKA) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023.The analyst firm set a price target for $11.00 expecting IKNA to rise to within ... Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday.

Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,

Nov 30, 2023 · (NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.

Follow. BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Atreca, Inc. (NASDAQ:BCEL) announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types, showing the investigational asset ...Nasdaq 14,261.45 +10.59(+0.07%) Russell 2000 1,800.24 -7.26(-0.40%) Crude Oil 75.75 +0.21(+0.28%) Gold 2,011.60 +8.60(+0.43%) Ikena Oncology, Inc. (IKNA) NasdaqGM - …Oct 18, 2022 · Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ... May 12, 2022 · First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ... To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...About Ikena Ikena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that discovers and develops biomarker-... Boston, Massachusetts, United ...Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Earnings and Valuation This table compares ...Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.. Details are as follows: Stifel Healthcare Conference, …

Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. (NASDAQ:IKNA) fell 12.3% to $1.43 in pre-market trading. Ikena Oncology recently reported worse-than-expected third-quarter revenue results.Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday.Aug 7, 2023 · Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.Aug 7, 2023 · Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... Oct 1, 2021 · BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced the first patient was dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, a 52-week Phase 3 study of ...

IKNA technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Ikena Oncology, Inc. is based on the most popular …Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)Source: Kantar Media. View the latest Ikena Oncology Inc. (IKNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.Nov 9, 2023 · Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656 BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%. Dec 17, 2021 · He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ... The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...

In the previous quarter, Ikena Oncology (NASDAQ:IKNA) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. IKNA's actual earnings.BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...May 12, 2022 · First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ... Instagram:https://instagram. most expensive home for sale in flwhat broker to use for forexkurt cobain guitaralibaba lululemon On September 12, 2023, BVF Inc. IL announced that it had increased its position in Ikena Oncology, Inc. (NASDAQ: IKNA) by 26.6% during the first quarter of this year. According to the company’s recent Form 13F filing with the Securities and Exchange Commission, BVF Inc. IL now owns a total of 3,169,164 shares of Ikena Oncology after acquiring an … illm stockspy forecast Check Out Our Latest Research Report on IKNA. Ikena Oncology Stock Up 9.8 %. Shares of NASDAQ IKNA opened at $1.46 on Monday. Ikena Oncology has a twelve month low of $1.02 and a twelve month high ...Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A … target price tracker Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company focused on developing novel cancer therapies targeting key ...Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%.